Alison Viles is a prominent inventor based in Thousand Oaks, CA (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of oral dosage forms for the drug apremilast. With a total of 3 patents to her name, Viles has demonstrated her expertise and commitment to advancing medical treatments.

Latest Patents

One of Alison Viles' latest patents focuses on formulations of apremilast. The patent describes oral dosage forms that include a core tablet with a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion. Additionally, the core tablet features a swellable layer made of one or more swellable polymers, along with a coating layer that contains at least one drug release orifice. These innovative oral dosage forms are designed for once-a-day dosing of apremilast and are suitable for treating diseases or disorders that can be improved by inhibiting phosphodiesterase subtype IV (PDE4).

Career Highlights

Alison Viles is currently employed at Amgen Inc., a leading biotechnology company known for its focus on innovative therapies. Her work at Amgen has allowed her to contribute to groundbreaking research and development in the pharmaceutical industry. Viles' dedication to her field is evident in her successful patent applications and her ongoing commitment to improving patient care.

Collaborations

Throughout her career, Alison Viles has collaborated with notable colleagues, including Nathan Bennette and William Brett Caldwell. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Alison Viles is a remarkable inventor whose work has significantly impacted the pharmaceutical industry. Her innovative formulations of apremilast and her contributions at Amgen Inc. highlight her dedication to advancing medical treatments. Viles' achievements serve as an inspiration to aspiring inventors and professionals in the field.